Immunoglobulin G4-related sclerosing disease

This early-phase trial tests a nebulized therapy called UC-EVs, derived from human umbilical cord cells, in adults with immune-mediated inflammatory diseases (such as IgG4-related disease or systemic sclerosis) that affect the lungs. Participants inhale the vesicles daily for 7 d…

This trial tests a single infusion of BCT301, a cell therapy made from stem cells that are engineered to target the immune system, in 6 adults with IgG4-related disease that has not improved with standard treatment. The main goal is to check whether the infusion is safe and toler…

This study tests a drug called inebilizumab in 15 children aged 2 to 17 who have IgG4-related disease, a rare condition that causes swelling and damage in organs. The drug is given through an IV and works by lowering certain immune cells to reduce inflammation. Researchers will c…

This phase III trial tests whether lenalidomide, an immune-modulating drug, can prevent disease flares in people with IgG4-related disease who are in remission. Participants receive either lenalidomide or a placebo for 52 weeks while tapering off steroids. The goal is to see if l…

This study tests a drug called IMM0306 in 125 people with IgG4-related disease, a condition where the immune system attacks organs causing swelling and damage. The goal is to see if IMM0306 can prevent disease flare-ups and allow patients to safely stop taking steroids. Participa…

This early-phase trial tests an injection called KSVCBD, a type of CAR-T cell therapy, in 60 adults with severe autoimmune diseases like lupus and scleroderma. The goal is to see if it's safe and to get a first look at whether it might help control the disease. Participants recei…

This early study tests a new drug called MTM-H-001 in 75 adults with B-cell-related autoimmune diseases, including lupus, multiple sclerosis, and rheumatoid arthritis. The main goal is to check safety and find the right dose. Participants receive the drug by injection, and resear…

This early-stage study tests a new treatment called LVIVO-TaVec400 in 44 people with severe autoimmune diseases like lupus, multiple sclerosis, and myasthenia gravis that have not responded to standard therapies. The main goals are to check the treatment's safety and find the rig…

This early-phase study tests a new treatment called KN5601, which uses specially engineered natural killer (NK) cells to target and destroy disease-causing immune cells in people with relapsed or refractory IgG4-related disease. The trial will enroll 18 adults and primarily check…